PRMT5 and neoplasm: Notably, combined treatment with type I PRMT inhibitors (GSK3368715 or MS023) and PRMT5 inhibitors (GSK3326595 or GSK3203591) slows in vitro and in vivo growth of tumor cells more effectively than treatment with either alone [14, 75].